<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01040559</url>
  </required_header>
  <id_info>
    <org_study_id>IDASPHERE</org_study_id>
    <nct_id>NCT01040559</nct_id>
  </id_info>
  <brief_title>Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas</brief_title>
  <official_title>Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas Combining DC Bead Microspheres Loaded With Idarubicin (Zavedos®): Phase I Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximal tolerated dose of idarubicin for
      chemoembolization of non resectable non metastatic hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatocellular carcinoma (HCC) is the fifth most common malignancy and the third most common
      cause of cancer-related death worldwide. Most of the patients are diagnosed at
      intermediate-advanced stage when the sole standard treatment is transarterial
      chemoembolization (TACE). In the literature, survival rates in TACE studies vary widely and
      finally, there is no suggestion for the best chemotherapeutic agent or the optimal treatment
      regimen.

      We hypothesise that the use of idarubicin (the most cytotoxic drug on HCC cell lines) in DC
      Bead would enhance the efficacy of TACE. The primary objective of the study is to determine
      the maximal tolerated dose of idarubicin in DC Bead for chemoembolization of non resectable
      non metastatic hepatocellular carcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity assessed according NCI CTC AE v3.0</measure>
    <time_frame>Within the first month after chemoembolization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective responses according criteria of the European Association for the Study of the Liver and according RECIST criteria.</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (EORTC QLQ-C30)</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameters of idarubicin and idarubicinol</measure>
    <time_frame>Within 72 hours after chemioembolization</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>Idarubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation: level0 = idarubicin 5mg, level1 = idarubicin 10mg, level2 = idarubicin 15mg, level3 = idarubicin 20mg, level4 = idarubicin 25mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>idarubicin</intervention_name>
    <description>Transarterial chemoembolization (in the hepatic artery) with idarubicin 5mg or 10 mg or 15 mg or 20 mg or 25 mg injected in a solution of 2ml DC Bead (300 µm-500µm); 1 unique course</description>
    <arm_group_label>Idarubicin</arm_group_label>
    <other_name>4-MDR</other_name>
    <other_name>IMI 30</other_name>
    <other_name>IDA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hepatocellular carcinoma cytologically or histologically proved or diagnosed according
             the criteria of the American Association for the Study of Liver Diseases(AASLD 2005)

          -  Three nodules maximum (unilobar disease without limitation in the number of nodules; 3
             maximum nodules if bilobar disease [satellite nodules &lt;1cm not included in the total
             sum])

          -  Child-Pugh score A or B7

          -  ECOG Performance Status &lt; 2

          -  Platelet count &gt; 50,000/µl and absolute neutrophil count (ANC) &gt;1,000/µl

          -  Serum creatinine &lt; 150 µmol/l

          -  Resting ejection fraction &gt; 50% (echocardiography or isotopic method)

          -  Age &gt; 18 years

          -  Signed written informed consent

        Exclusion Criteria:

          -  Patients eligible for surgical resection or hepatic transplantation or radiofrequency
             ablation

          -  Extrahepatic metastases

          -  Known gastrointestinal bleeding up to 30 days before study entry

          -  Patients with anticoagulant treatment

          -  Evidence of portal vein thrombosis

          -  Pregnancy

          -  Clinically serious infection

          -  Known hypersensitivity to anthracyclines

          -  Known hypersensitivity to contrast medium
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent BEDENNE, MD Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Dijon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de DIJON</name>
      <address>
        <city>Dijon</city>
        <state>Burgundy</state>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2009</study_first_submitted>
  <study_first_submitted_qc>December 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2009</study_first_posted>
  <last_update_submitted>January 8, 2013</last_update_submitted>
  <last_update_submitted_qc>January 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2013</last_update_posted>
  <responsible_party>
    <name_title>Professor Laurent Bedenne</name_title>
    <organization>Centre Hospitalier Universitaire Dijon</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Idarubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

